Effects of intracavernous injection of P2X3 and NK1 receptor antagonists on erectile dysfunction induced by spinal cord transection in rats

Andrologia ◽  
2014 ◽  
Vol 47 (1) ◽  
pp. 25-29 ◽  
Author(s):  
C.-L. Li ◽  
X.-L. Yang ◽  
J.-J. Wang ◽  
G.-H. Du ◽  
W.-M. Yang ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Erectile Dysfunction ◽  
Spinal Cord Transection ◽  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Intracavernous Injection ◽  
Nk1 Receptor Antagonists

scholarly journals The Role of CGRPin Nociception?

2001 ◽  
Vol 1 ◽  
pp. 19-19 ◽  
Author(s):  
R. G. Hill
Keyword(s):  
Spinal Cord ◽  
Pain Perception ◽  
Sensory Ganglia ◽  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Peripheral Tissues ◽  
Sensory Neurones ◽  
Antinociceptive Effects ◽  
Nk1 Receptor Antagonists

The failure of NK1 receptor antagonists to show analgesic activity in clinical trials in spite of abundant preclinical evidence for a role of this neuropeptide in nociception, makes it somewhat dangerous to speculate on the nociceptive role of other neuropeptides, especially with respect to therapeutic utility of receptor antagonists! However, CGRP is the primary afferent peptide with the strongest evidence of a role in pain perception. It is found in a greater proportion of sensory neurones than other peptides and is a constituent of A[delta ] as well as C-fibres. Inflammation of peripheral tissues upregulates production of CGRP in sensory ganglia, coincident with the development of hyperalgesia, and CGRP knockout mice have attenuated hyperalgesic responses. CGRP is released into the dorsal horn of the spinal cord (DHSC) by noxious peripheral stimuli and excites nociceptive DHSC neurones on local application. The peptide antagonist CGRP8-37 blocks the response to exogenous CGRP and can reduce the response of DHSC neurones to noxious peripheral stimuli. CGRP8-37 has also been shown to have behavioural antinociceptive properties when given intrathecally. Conversely, injection of CGRP itself to the PAG or n. accumbens has been reported to have antinociceptive effects that are reversed by CGRP8-37. With the advent of potent non-peptide antagonists such as BIBN4096BS we should soon be able to determine whether systemic blockade of all CGRP receptors produces antinociception without limiting side effects.

Discovery of orally bioavailable NK1 receptor antagonists

2003 ◽  
Vol 13 (3) ◽  
pp. 437-442 ◽  
Author(s):  
C. Genicot ◽  
B. Christophe ◽  
P. Collart ◽  
M. Gillard ◽  
L. Goossens ◽  
...  
Keyword(s):  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Orally Bioavailable ◽  
Nk1 Receptor Antagonists

Oral anti-hyperalgesic and anti-inflammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig

Pain ◽  
2000 ◽  
Vol 87 (3) ◽  
pp. 253-263 ◽  
Author(s):  
Elizabeth A. Campbell ◽  
Clive Gentry ◽  
Sadhana Patel ◽  
Bruce Kidd ◽  
Simon Cruwys ◽  
...  
Keyword(s):  
Guinea Pig ◽  
Inflammatory Activity ◽  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Inflammatory Hyperalgesia ◽  
Anti Inflammatory ◽  
Nk1 Receptor Antagonists

Bioactive conformations of peptides and mimetics as milestones in drug design: Investigation of NK1 receptor antagonists

1995 ◽  
Vol 2 (3-4) ◽  
pp. 125-134 ◽  
Author(s):  
Solo Goldstein ◽  
Michel Neuwels ◽  
Florence Moureau ◽  
Didier Berckmans ◽  
Marie-Agn�s Lassoie ◽  
...  
Keyword(s):  
Drug Design ◽  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Nk1 Receptor Antagonists

The site of the anti-emetic action of tachykinin NK1 receptor antagonists may exist in the medullary area adjacent to the semicompact part of the nucleus ambiguus

1999 ◽  
Vol 818 (2) ◽  
pp. 439-449 ◽  
Author(s):  
Hiroyuki Fukuda ◽  
Emi Nakamura ◽  
Tomoshige Koga ◽  
Naohiro Furukawa ◽  
Yasuteru Shiroshita
Keyword(s):  
Nucleus Ambiguus ◽  
Nk1 Receptor ◽  
Receptor Antagonists ◽  
Nk1 Receptor Antagonists
Sign in / Sign up

Export Citation Format

Share Document